Cigna Group (CI) is a "clear standout" in the volatile health-care insurance industry, thanks in part to a "diversified and stable earnings flow," Oppenheimer said Friday in a report.
"The company's service-based platform leaves minimal exposure to risk-products that are igniting volatility across the managed care space," Oppenheimer said.
Cigna's Evernorth division has been capitalizing on surging demand for GLP-1 medications to treat Type 2 diabetes and obesity, starting programs that cap out-of-pocket costs and streamline access, the report said.
Cigna "remains one of the most attractive stocks to own" with "an attractive portfolio that should yield solid growth," the report said.
Oppenheimer reiterated its outperform rating on Cigna stock and price target of $375.
Price: 314.71, Change: +0.31, Percent Change: +0.10
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.